Clinical Trial

A Phase I/Ⅱ Clinical Trial for Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Ankylosing Spondylitis

Study acronym: HS_SW01
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS\_SW01 cells injection) in patients with Ankylosing Spondylitis. Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-10.
Trial Details
NCT Number NCT07534644
Lead Sponsor Shenzhen Huishan Biotechnology Co., Ltd.
Collaborators: Southern Medical University, China
Conditions Ankylosing Spondylitis
Enrollment 18 participants
Start Date 2026-04-10
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-20